HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam TechnologyBusiness Wire · 5 days ago
HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk PatientsBusiness Wire · Oct 15, 2026
HeartBeam Secures FDA Designation for At-Home Heart Attack Detection SystemBenzinga · Oct 5, 2026
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack AssessmentBusiness Wire · Oct 5, 2026
HeartBeam, Inc. (NASDAQ:BEAT) Stock Has Consensus Price Target of $4.00Defense World · Oct 1, 2026
HeartBeam, Inc. Letter to ShareholdersBusiness Wire · Sep 21, 2026HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.09 | -$0.10 | Miss |
| May 13, 2026 | -$0.14 | -$0.12 | Beat |
| Mar 12, 2026 | -$0.13 | -$0.14 | Miss |
| Nov 13, 2025 | -$0.16 | -$0.15 | Beat |
| Aug 13, 2025 | -$0.16 | -$0.15 | Beat |
| May 13, 2025 | -$0.15 | -$0.18 | Miss |